EXHIBIT 1022
`
`CURRICULUM OF VITAE OF DONALD A. WEIBE
`
`; Infopia Ex. 1022 pg. 1
`
`
`
`

`
`’
`
`'
`
`..
`
`7
`
`'
`
`.
`
`-
`
`‘ 1/12/is
`
`. B’ACKG’HOUND~lNFORMATlON.‘
`Donald Alan Wiebe’ 2 3
`University of Wisconsin—Madison
`D4/252 Clinical Science Center
`University Hospital & Clinics
`600 Highland Avenue
`V Madison, Wisconsin 53792-2472
`(608) 263-1495
`
`'
`
`FORMAL EDUCATION‘
`'-
`»
`1973 Ph.D. Degree
`_
`.
`.
`Major: Organic Chemistry '
`Thesis: "Synthesis of Polyfluorinated Aldehydes, Acyl Halides, and _
`~_
`Carboxylic Acids",’Dis.’Abstr. Int B jg 2535 (1973).
`. Major Advisor: Donald .J.’ Burton, Ph;D:
`-
`’
`'
`.
`.j
`Institution: University of Iowa, Iowa City ~
`
`'
`
`4
`
`H
`
`7
`
`'
`
`1970 M.S. Degree‘
`'
`" Major: Organic. Chemistry
`institution: Universit'y’ofl'owa,'lowa City .
`
`_
`
`1967 13.3. Degree
`.. Major: Chemistry
`institution: University of Wisconsin—La Crosse
`
`-
`C
`PROFESSlONAL CERT|FlCATIOl\l
`Diplomat, American Board of Clinical Chemistry — 1983
`Fellow, National Academy of Clinical Biochemistry»- 2000
`
`a
`
`,
`
`POSlTlONS HELD
`
`1990 - ‘present
`.
`
`V
`j
`Associate Professor
`\ Department of Pathology & Laboratory Medicine
`School of Medicine
`.
`«
`°
`~
`. University of Wisconsin—Madison
`
`'
`
`2002 —~ present. .
`>
`
`Z
`
`1985; present
`v
`.
`'
`
`-
`
`‘V .1987 ~ 1989
`
`" ‘19é4—199’e
`
`‘
`
`Director, Clinical Chemistry Laboratory
`University of Wisconsin Hospital & Clinics-
`University of Wisconsin-Madison
`~ Director, Toxicology -Laboratory Service
`University of Wisconsin"Hos~pital '& Clinics
`University of Wisconsin~Madison
`Affiliate Assistant Professor
`_ WSchool_ofAllied Health Professions_ ‘
`_
`-. University‘of‘Wisconsin~Madison
`~
`:
`‘
`Associate Director, fClinical.Chemistry Laboratory.
`University ofV\'/_\/isconsin Hospital & Clinics
`
`-
`
`.
`
`‘_
`
`:
`
`.
`
`lnfopia Ex..~1022 pg. 2
`
`

`
`~,1984 — 1990
`
`1989 -.1984
`
`1980 - 1983
`
`University of’\_/\Iisconsi‘n—Madison
`
`-
`1
`~
`Assistant Professor
`, Department of Pathology & Laboratory Medicine
`School of Medicine,‘
`University ofWisconsin—Madison'
`
`‘
`
`‘
`
`‘
`
`»
`
`Research Scientist
`1CIinic“aI Chemistry Division -
`Center for Environm_ental Health
`Centers for Disease Control
`'
`Atlanta, Georgia
`
`‘
`
`Visiting Scientist
`Clinical Chemistry Division
`Center for Environmental Health
`Centers for Disease Control
`Atlanta, Georgia ‘
`
`197841980
`
`‘Post-Doctoral Fellowship. '
`Department of‘Patho|ogy
`University of Iowa, Iowa City
`
`~ 1978- 1978”
`
`.1972 — 1.978
`
`1972 — 1978
`
`"197o~1972
`
`“ 1997-1979
`
`Associate Research Scientist
`‘ Department of Internal Medicine
`University of Iowa, Iowa City
`
`~
`1
`Assistant Research Scientist! ’
`Department of Internal-Medicine
`University of Iowa, Iowa City
`
`Director, Lipid Research Laboratory
`Department of Internal Medicine
`University of Iowa, Iowa City '
`
`Research Assistant
`Department of Chemistry
`University of Iowa, Iowa City
`
`I
`A Teaching ‘Assistant
`Department of Chemistry
`University of Iowa, Iowa City
`
`.
`
`‘ HONORS AND Aw/‘Maps
`9
`’
`"
`Friend of ASCLS-Wisconsin 2014
`;2oo7 1'
`Albert A. Dietz Service Award Chicago,Sec_tion AACC
`Samuel R. ‘Natelson Research Award Chicago Sectio
`n AAC,C, 2005
`, Past Chair Award Chicago: Section AACC, 2903
`
`Infopia Ex.'.102'2 pg. 3
`
`

`
`‘Gerald R Cooper Service Award from the. American Association for Clinical
`' Chemistry, Lipids and Lipoproteins Division, 1998 ~
`.
`Lipids and Lipoproteins Division Leadership Award, 1990
`NIH Recognition & Appreciation of Contribution to the NHLBI Lipid
`~ Research‘Clinics Program, 1982
`'
`~
`'
`g
`,
`y
`‘
`A
`Honors Chemical Society of Phi Lambda Upsilon, elected 1970
`
`~
`'
`
`PROFESSlONAL sociETY MEMBERSHIPS 1
`
`American Chemical Society, 1968 - present
`.
`Alpha‘ Chi Sigma, 1968 - present’
`American Association for Clinical Chemistry, 1974 - present
`Lipids and 'Lipoproteins~ Division
`TDM and Toxicology Division
`Nutrition Division
`"
`
`.
`
`.
`
`Wisconsin Lipid Club,.199.0-present
`Clinical Ligand Assay Society, 1996 -present
`Midwestern Therapeutic Drug Monitoring & Toxicology 1996 - present
`
`.
`
`.
`
`.
`
`. PUBLICATIONS
`Papers published in refereed journals: ‘
`
`1. Douglas G. Naae and Donald A. Wiebe: Mass spectral correlations of
`halogenated 1,1,1,3,3,3-hexafluoropropanes and 1,1,,1-trifluoroethanes.
`Qjg. Mass. Spectr. 4: 1203-1206 (1974):
`‘
`
`. 2. Donald A. Wiebe and Donald J. Burton: Chemoselective halogenation
`of 2-hydroperfluoroalkyl aldehydes; J Flu Chem139 (2012) 4-11.
`"3; ‘Laboratory.Methods Committee otthe Lipid Research Clinics Program
`of the National Heart, Lung and Blood institute: ‘Cholesterol and
`.
`triglyceride concentrations in serum/plasma pairs. g)li_n. Chem. 28: 60-63
`(1977).
`'
`«
`
`4. C. Patrick Bums, Shiao-Ping, L. Wei, Ian R. Welshman, Donald A.
`Wiebe, and Arthur A. Spector: Fatty acid utilization by L1210 murine
`leukemiacells. Cancer Research Q; 1991-1997 (1977).
`
`. 5; John J. Albers, ‘G. Russell Wamick, Donald Wiebe, et.al.: Multi-
`laboratory comparison of three heparin-Mn“ precipitation procedures .
`for estimation of high density lipoprotein cholesterol.
`Chem. 25:»
`853-856 (1 978).
`-
`g
`.
`s
`
`1 6. John T. Hayford, Mark~M. -Danney,- Donald Wiebe, Susan Roberts, and
`Robert C. Thompson: Triglyceride integrated concentrations: effectof
`variation of source and amount of dietary carbohydrate.‘ Am. ;_J_._ gin.
`Nutrition 32: 1670 -1678 (1979).
`‘
`'
`-
`
`"
`
`lnfopia Ex. 1022- pg. 4
`
`

`
`7. Arney i\lordoy, Bridit Swensson, Donald. A. Wiebe ,and John C-. Hoalc
`Lipoproteins andthe inhibitory effects of human endothelial cells upon
`platelet function. Circulation Research 4;: 527-534 (1978).
`
`8. Arney Nordrziy, Bridit Swensson, Donna Haycraft, John C. Hoakgand
`Donald A. Wiebe: The influence of agejsex and the use of oral
`"
`contraceptives? on the inhibitory effects of endothelial cells and PGI2.
`(prostacylin) on platelet function. Scand._g; 91‘ Haemat. fir 177~1 871 ‘
`(1978).)
`.
`v
`.
`-
`V
`.
`
`i 9. Helmut ‘G. Schrott; William R. Clarke, Donald A, Wiebe,,Willia"m E.
`~ Connor, and Ronald M. Lauer: The Muscatine family studies program: i.
`" increased coronary mortality in relatives of hypercholesterolemic school ,
`children. Circulation _@: 320-926 (1979).
`
`10. Enrique Chaves—Carballo, Guy A. Carter,and Donald A: Wiebe:
`Triglyceride and cholesterol ‘concentrations in whole serum and serum ,
`‘ lipoproteins in Reyes Syndrome. Pediatrics 6-<_1,:’592—597 (1979).
`‘ 1.1. Helmut G. Schrott, William R. Clarke, Peter Abrahams,‘Don_a|d A.
`Wiebe, and Ronald M. Lauer: Coronary artery disease mortality in
`relatives of hypertriglyceridemic school children and the lvluscatine study.
`fl’9Ll8_’f'|Qll £3.52: 300-305 (1982)-I
`'
`-
`
`12. Donald A. Wiebe and Thomas Bernert: The influence of incomplete
`‘ cholesterol ester hydrolysis on cholesterol measurement by enzymatic
`methods. %. Chem. __3_q: 852-356 (1984).
`
`13. G. R. Cooper, S. J. Smith, D. A. Wiebe, M. Kuchmack, and W. H.
`Hannon: International survey of apolipoproteins A—l and B
`measurements (1983-1984): _C_li_n.«Chem. 31: 223228 (1984).
`14.‘ Donald‘A. Wiebe and S. Jay Smith: Comparisonofsix high-A
`densitylipoprotein isolation methods using the cholesterol reference
`method for quantitation. %. ‘Chem. Q: 746-750 (1985).
`15. Ellen R. ‘Massaro, Ernest C. Borden,Michael Hawkins, Donald A.
`Wiebe, and Earl S. Shrago: Effects of recombinant interferon alphaz
`treatment upon lipid concentrations and composition. Journal of
`interferon Research 6: 665-662 (1987). ,
`16. l.‘iBruce Rosenzweig, Donald Wiebe, Ernest Borden, Barry Storer,
`and, Earl S. Shrago: Plasma lipoprotein changes in humans induced by
`f i3—interferon. Atherosclerosis 6_7: 261-267 (1987).
`
`.Gary,L. Lensmeyer, Donald A. Wiebe, and Ian H. Carlson:
`17.
`identification‘ and analysis of ninemetabolites ofcyclosporine in whole
`blood by liquid chromatography: Part 2. Comparison of patient results.
`9&1. §§_:'l851‘-1855 (1987).
`~
`_
`‘
`»
`
`‘
`
`,
`
`lnfopia Ex. 1022 pg. 5
`
`

`
`18. Gary L. Lensmeyer, Donald A. Wiebe,~and lan H. Carlson:
`identification and analysis of ninemetabolites ofcyclosporine in whole
`‘~
`, blood by liquid chromatography: Part 1. Purification of analytical
`- standards/optimization of assay. flu. Chem. §_C;:1841-1850 (1987).
`
`19. Arthur A. Eggert, Gary J. Smulka, Donald A. Wiebe, Dennis E. Dowd,
`: and Sharon K. Wagner: Real~time monitor of STAT chemistry requests
`with a clinical laboratory information system.
`informatics i_n.‘Pathology.2_:
`.266-271‘ (1987).
`‘
`‘
`-
`'
`1
`8
`"
`
`20. Michael P. Vrabec, Michael B. Shapiro, Elizabeth Koller, Donald A.
`Wiebe, Jill Henrichs,. and John J. Albers: Ophthalmic observations in
`~lecithin:cholesterol acyltransferase (LCAT) deficiency. Archives 9;‘ A
`Ophthalomolgy JQQ: 225—229 (1988).
`-
`‘
`
`21. David D. Koch, David J. Hassemer, Donald A. Wiebe, and Ronald H.
`Laesslg: Testing cholesterol accuraoy——performance of several common
`laboratory instruments. JAMA @: 2552-2557 (1988). ~
`’
`'
`22. GL Lensmeyer,‘Wiebe DA, Carlson lH: Deposition of nine metabolites
`of cyclosporine in human tissues", bile, urine and whole blood. Transplant
`Proc. _2_Q: 614-22 (1988).
`
`A 23. Gary L. Lensmeyer, Donald A. ’V\_/iebe, and lan H. Carlson:
`» Distribution ' of cyclosporin‘ (CsA) metabolites among plasma/cells of whole
`blood:
`Effect of temperature, hematocrit, and metabolite concentration.
`_C_lin. Chem. 35:56-63 (1989).
`._
`
`l. Bruce Rosenzweig, Donald A.‘Wiebe, Jacquelyn A. Hank,*.John J.
`24.
`Albers, Janet L. Adolphson, Ernest Borden, Earl S. Shrago, and Paul M.
`‘ Sondel: Effects ofinterleukin-2 (ll_'—2) on human plasma lipid, lipoprotein,
`and C—reactive protein. Biotherapy 2: 193-8 (1990).
`
`25. ' Gary,Lensmeyer, lan l-l. Carlson, and Donald A. Wiebefstudy of
`three commercial polyclonal immunoassays for cyclosporin (CsA) in whole
`blood. Part 2: Metabolite cross—reactivlty study. C_lii1. Chem. 86; 119—23
`(1990).
`.
`~
`.
`
`26. Michael J. Strassman, Gary Lensmeyer, Donald A. Wieb_e, and Ian H.
`Carlson:' Study of three commercial polyclonal immunoassays for
`cyclosporin (CsA) in whole blood. Part 1: Patient specimen comparison.
`Qli_n. (mi. flfl 15-8 (1999).
`'
`'
`’
`‘
`
`- 27. Anthony G. Hejka, Michael Poquette, Donald~A. Wiebe, and Robert
`W. Huntington: Fatal intravenous injection ofmonootanoin. Ai_m J .
`‘Forensic Med Path. fl: 165-70 (1990,).-
`_
`'
`'
`~
`~
`
`1
`
`~ 28.. _ Pich'ard_.R. Love’, Polly A. Newcombn, Donald A. Wiebe, Tanya‘S.‘ ’
`-Surawicz,‘V. Craig Jordan, Paul P. Carbone, and David L. DeMets:'
`.
`‘
`.
`Effects
`of tamoxifen therapy on lipid and lipoprotein levels in y
`
`‘
`
`y
`
`lnfopia Ex; 1022,pg. 6'
`
`

`
`.'
`
`postmenopausal
`patients with node—n.eg'a_tive breast cancer. J flag Cancer
`l_n§1. 82: 1327-
`'32 (1990).
`(29. Gary L. Lensmeyer, Donald A‘. Wiebe, lan. Hi. Carlson, and R.
`Subramanian:-Concentrations of cyclosporin A and its metabolites in
`human tissues postmortem. J Anal. I9_x_. 1_5: 110-5 (1991).
`
`30. David‘J. Hassemer,'Donald A.‘-Wiebe, Ronald H. Laessig, and David
`D. Koch: Response to Therapy of hypercholesterolemia; standardization
`of cholesterol measurements. (letter to the editor) JAMA @: 375-6
`(1990).
`V
`'
`‘
`’
`~
`-
`
`~
`
`‘
`
`9
`
`_
`’ 31. ‘Donald A. Wlebe: Response to Advantages of initial population
`screen with determinations of total cholesterol in serum and of lipoproteins
`by.electrophoresis.' _Qli_n_. Chem. 3_6 :2010r(1990).
`‘
`
`32. W. Greg Miller, Jacob B. Levine, Mike Santulli, Kerry J. Flom, Neil
`Greenberg, Aurthur Kessner, Wendell R. O_‘Nea|, Donald A. Wiebe, and
`Carol Adiletto: Effect of freezing on cholesterol in individual sera. Clin.
`gm. 3]: 584-5 (1991).
`’
`'
`A
`33. James O. Westgard, Per Hytloft; and Donald.A.vWie'be: Laboratory ‘
`process specifications for assuring quality in the National Cholesterol
`Education Program (NCEP)._Q_li_r1. Chem. 3_7_: 656-61 (1991).
`34. Gary L. Lensmeyer, DonaidA. Wiebe, and Thomas Doran:
`Application of the Empore solid—phase extraction membrane to the
`isolation of drugs from blood. 1. Amiodarone and desmethylamiodarone.
`Ther.’Drug Monit. 1_3: 244-250 (1991).
`'
`
`35. Joel B. Hansen, H. Phillip Lau, Christopher J. Janes, Warren K..
`Miller, and Donald A. Wiebe: Rapid ‘and specific cyclosporine assay for
`the DuPont acadisorete clinical analyzer performed on wholeblood. J
`gi_n. l__a_b. Aral. §_:187—1~92 (1991).
`’
`~
`I
`
`'
`
`36. Miller WG,Levine JB,Santulli M; Flom KJ, Greenberg N, Kessner a,
`O’Neal WR, Wiebe DW, Adiletto C. Effect of freezing on cholesterol in
`individual sera. Clin. Chem._ 37: 584-5 (1991)
`~
`‘
`-
`
`‘
`
`T
`
`37. John C. Schultz, Gary L. Lensmeyer, Nasrollah T. Shahidi, Donald A.
`Wiebe, and lan Carlson; Synergistic and antagonistic effects of
`combinations of cyclosporin A and its metabolites on inhibltioi-i?’of PHA-
`induced lymphocytetransformation in vitro. Biochernical.Pharm. 4_2_:
`*
`_ 14034410 (1991).
`s
`.
`'
`6
`
`.
`
`38. Richard R: Love, Donald A. Wiebe, Polly A. Newcomb, Linda;
`Cameron, Howard Leventhal, V. Craig Jordan, Jan-Feyzi, and David L.
`DeMets: Cardiovascular risk factor efiects of Tamoxifenin
`.
`‘
`postmenopausal women. Arm. intern. fit, 1fl:860—864 (1991).
`
`—
`
`'
`
`‘
`
`.
`
`-
`~
`
`.
`
`..
`
`'
`
`‘
`
`‘
`
`«
`
`A
`
`A
`
`lnfopia Ex. 1o22«pg. 7
`
`I
`l
`
`E
`K
`{
`l
`
`E
`‘T
`
`
`
`

`
`39.. James O. Westgard and Donald A.. Wiebe‘: Cholesterol operation
`process specifications for assuring quality required by CLiA proficiency »
`testin_g. _Qli_n. Chem. 31: 1938-1944 (1991);
`
`.
`
`‘
`
`I
`
`40. Gary L. Lensrneyer, Donald A. Wiebe, and Barbara Darcey:
`Application ofa novel solid~phase sorbent (E_mpore®,Membrane) toxthe
`iisoiation of tricyclic antidepressant drugs from Blood‘. L Chromatog.
`§g_i. Q: 444—449,(199‘1').
`.
`‘
`41. 4 Gary L. Lensmeyer, Donald A. Wiebe, and Thomas C. Doran:
`Application of the Empore soiid~phase extraction membrane to the
`~ isolation" of drugs from blood: ii mexilitine and flecainide. Ther. Drug
`Monit. 14: 408-415 (1992).
`
`42. Donald A. Wiebe and James O. Westgard: Cholesterol-—a model
`system to relate medical needs with analytical performance. gin. Che
`§_9_: .1504-1513 (1993).
`e
`’
`
`.
`
`43. Richard R. Love, Donald A. Wiebe, Jan Feyzi, Polly A. i\iewc'omb,
`and Richard J. Chappell: Effects of tamoxifen on cardiovascular risk
`factors in postmenopausal women afterfive years. JNCI §§: 15344539
`(1994).
`’
`‘
`
`44. Gary L. Lensmeyer, Carol.Onsager, lan H. Carlson, and Donald A.
`A Wiebe: Use of particle-loaded membranes to extract steroids for HPLC
`analyses: improved analyte stability and detection. J; Chrom. A, 691:
`229-246 (1995).
`’
`- 4'5. Gary‘L. Lensmeyer, Terry Kempf, Barry E. Gidal, and Donald A.
`Wiebe: Optimized method forgabapentin in serum’ by high performance
`liquid chromatography. Therapeutic Drug Monitoring 17251-258 (1995).
`
`,
`
`:Medica|
`46; ‘McBride P; Plane MB, Underbakke G, Hill R,'Wiebe D.
`students health habits: Do_Future physi'cians,hjave healthy lifestyles?
`Wisconsin Medical Journal 1995;94:45—46. ”
`.
`
`.
`
`47.~David A. Wells, Gary L. Lensmeyer, and’Donaid A. Wiebe: Particle~ -
`loaded membranes as an alternative to traditional packed-column
`sorbyents for drug extraction: ln—depth compartive study- ‘L Chrom.
`33:386-392 (1995)’.‘.
`‘
`'
`'
`.
`»
`
`48. Gary L.’ Lensmeyer,‘ Barry E. Gidal, and Donald A. Wiebe: Optimized
`« high—performance liquid chromatography method for lamotrigine in serum
`‘with concomitant determination of phenytoin, carbamazepine and
`carbamazepine epoxide. TherVDrug Monit 19:292~300(1997).
`49. Patricia C. Faliest-Strobl, Eiin‘Q|afsdottir, Donald (A. Wiebe, and ~
`James~O. Westgard; Comparison of NCEP performance specifications
`‘ for triglycerides, HDL—, and LDL—cholesteroi_with operating specifications:
`
`A
`
`A
`
`lnfopia Ex. 1022 pg‘. 8
`
`

`
`based~'on clinicaland analyticalgoals. Clin. Chem. 4_3:
`(1997).
`.
`._ V
`.
`'
`‘
`’.
`
`64-2168 _
`
`J 50. Nader Rifai, Thomas G. Cole, Elizabeth lannotti, Terence Law;
`Michael Macke, Richard Miller, Dennis Dowd, and Donald A. Wiebe;
`~ Assessmeht.of interlaboratory performance in external proticiencytesting ‘
`programs with a direct HDL-cholesterol assay; Qfl Chem:44:1452—1458 '
`(1998).
`.
`~
`'
`‘
`.
`A
`
`'
`
`‘51. Todd M. Alien, John Sidney, Marie-France del Guerico, Rhonda L.
`Gliclgman, Gary L. Lensmeyer, Donald A. Wiebe, C. David Pauza, R. Paul
`Johnson, Alessandro Sette, and ‘David I. Watkins. Characterization of the
`peptide binding motif of a Rhesus MHC classl molecule (mamu—A*01) that
`binds and immunodominant.CTL epitope from SIV. Journal o_f
`Immunology, 160:6062—6071 (1998);
`’
`
`Stein, Jon G. Keevil, Donald A. Wiebe, Susan
`52. James
`Aeschlimann, and John D. Folts. Purple grapejuioe improves endothelial
`function and reduces the susceptibility of LDL cholesterol to oxidation in
`patients with cardiovascular disease. Circulation", 100:1050—1055 (1999).
`
`.
`53. James H Stein, Melissa A. Klein, Jennifer L. Bellehumer, Patrick E.
`McBride, Donald A. Wiebe, James D. Otvos, and James M. Sosman. Use
`of human immunodeficiency Virus-1 protease inhibitors is associated with
`endothelial dysfunction and atherogeniclipoprotein changes. Circulation
`104:257-262 (2001).
`y
`6
`‘
`’
`
`'
`
`54. Mandy L. Porter, Christian G. Krueger, Donald A. Wiebe,‘ David G.’
`Cunningham, and Jess D. Reed. Cranberry proanthocyanidins associate
`with low’-density iipoprotein and inhibit in vitro copper—induced oxidation.
`Journal Q‘ E Science gf Food fl Agriculture 81:1306—1313 (2001).
`
`55. Eric J. Chou, Jon~G. Keevil, Susan Aeschlimann, Donald A. Wiebe,,
`John D, Folts, and James H. Stein. ingestion of purple grapejuice
`improves endothelial function in patients with coronary heart disease. E
`American Journal 9;‘ Cardiology, 882553555 (2001).
`'
`‘y
`
`.
`
`56. James H Stein, Cynthia M.) Carlsson, Kristi Papcke—Benson, Jean A.
`_ Einerson, Patrick-E. MoBride,,and.Donald A. Wiebe. inaccuracy of
`-
`portable lipid analysis in patients with hyperlipidemia. Clin. Chem. 48: 2842
`.290 (2002).
`57. Andrea R. Terrell, -Thomas M. Daly, Karl G. Hock, Daniel C.3Kilgore,.
`Tie Q-. Wei, 'Sharon_Hernandez, Don Weibe, Leona Fields, Leslie M.-
`Shaw, and Mitchell.G. Scott. Evaluation of a i\lo—Pretreatrnent Cyclosporin‘
`A Assay on the Dade Behring Dimension RXL Clinical Chemistry Analyzjer .
`Q_i‘l_$__fTi.‘481‘1“0.5.9~".l065 (20,02).
`1
`58. Alexander Turchin, Donald A. Wiebe, Ellen W. Seely, T Graham, '
`Walter Longo, and Robert Soiffer; Severe hypercholesterolemia mediated
`
`V
`
`«
`
`lnfopia Ex. 1022 pg. 9 ’
`
`,
`
`_
`
`‘
`
`“
`
`r
`
`l
`
`l
`
`
`
`

`
`in patients with chronic graft—versus host ‘disease of the
`by lipoprotein
`liver: a case series and review of the literature. Bone Marrow -
`
`Transplantation 35: 8589 (2005).
`
`59. James H. Stein, Michelle A. Merwo'od, Jennifer B; Bellehumeur;
`Patrick E..’McBride, Donald AWiebe, and James M. Sosman._Post— .
`prandial lipoprotein changes in patients taking. antiretroviral therapy for
`human immunodeficiency virus infection. Arterioscler. Thromb. Vasc.
`l_?;io_l., 25: 390-405 (2005).
`~
`:
`<
`-.
`
`.
`
`60. Gary L. Lensmeyer, Donald A. Wiebe, Neil Binkley, a'nd,Marc K.
`Drezner. I.-lPLC Method for 25-Hydroxyvitamin D Measurement:
`.
`Comparison with Contemporary Assays Clin. Chem. 52: 1120-1126
`(2006).
`,
`. 3
`‘
`.
`9
`_
`.
`.
`61". David A..Katz, David F. Jarrard, Colleen McHorney, Steven L. Hills,
`Donald A. Wiebe, and Dennis G. Fryback. Health Perceptions in Patients
`Who Undergo Screening and Workup for Prostate Cancer. Drology 69;
`' 215220 (2007).
`‘
`
`Severe .
`162. Zidan H, Lo 8, Wiebe D, Talano J Alemzadeh
`hypercholesterolemia mediated by lipoprotein X in a pediatric patient with
`chronic graft-versus—host disease of the liver. Pediatr Blood Cancer 50:
`- 1280-1281 (2008).
`
`63. Donald A. Wiebe. The Cholesterol Wars: The Skeptics vs. the
`Preponderanoe of_Evidence. Daniel Steinberg. Clin. Chem. 55:1441-1442 ’
`(2009).
`,
`A
`1
`
`A
`
`64. Yetley EA, Pfeiffer CM, Schleioher RL, Phinney KW,‘ Lacher DA,
`Christakos S, Eckfeldt JH, Fleet JC, Howard G, Hoofnagle AN, Hui SL,
`' Lensmeyer GL," Massaro J, Peacock M, Rosner B, Wiebe D, Bailey RL,
`‘. Coates PM, Looker AC, Sempos‘C~, Johnson CL, Picciano MF; Vitamin D
`Roundtable on the NHANES Monitoring of Serum 25(OH)D: Assay
`‘
`Challenges and Options-for Resolving Them. J Nutr. 2010 g
`Nov;140(11):2030S-45S.
`
`,
`
`65. Eiinkley N, Krueger DC, Morgan S, Wiebe D. Curient status’ of clinical
`25-hydroxyvitamin D measurement: an assessment of between—laboratory
`agreement. Clin Chim Acta. 2010 Dec 1,4;411(23-24):1976—82.
`66. Lensmeyer G, Poquette M, Wiebe D,‘and Binkley N. The C-3 epimer
`of 25—hydroxyvitamin D3 is ‘Present in Adult Serum. Journal of Clinical
`Endocrinology & Metabolism, 2012 Jan;9"/(1)2163-8.
`
`’
`
`67. Hedman CJ, ‘Wiebe DA, Day 8, Plath J, Kemnitz‘ JW,‘ and Ziegler TE.
`Development of a Sensitive LC/MS/MS Method for Vitamin D Metabolites,
`1,25 Dihydroxyvitamin D.2&3 Measurement Using a Novel Derivatization
`Chemistry. Journal of Chromatography B, 953—4 (2014) 62-7.
`
`lnfopia Ex. 1022 ‘pg. 10
`
`«
`
`
`
`

`
`.~ 68. Wiebe D and Binkley N.- Case Report: Three Patients With Substantial
`Serum Levels of 3-Epi,~25(OH)D Including One With 3—Epi—25(OH)D2
`While on High-dose Ergocalciferol. Journal of Clinical Endocrinology &
`Metabolism, 2014 Apr;99(4):1 117-21.
`»
`'
`
`invited papers published in (refereed) conference proceedings:
`
`-
`
`-
`
`‘
`
`1._ Donald A. Wiebe, l. Bruce Rosenzweig, Frank V. Ruzicka, Earls.
`Shrago, and Ernest C.‘ Borden: Selective association of high density
`lipoprotein.(HDL) with interferon beta serine. Proceedings of the
`international Society for Interferon Research. In: The Biology of the
`Interferon System 1986, eds. K Cantrell and H.Schellekens (Boston:
`Martinus Nijhott Publishers, 1987), pp. 19-23.
`-
`'
`
`2. Gary L. Lensmeyer, .Don‘ald,A. Wiebe, and lan C. Carlson: Deposition
`of nine metabolites of cyclosporine in human tissues, bile, urine, and
`whole blood .1 ln: Transplantation Proceedings Vol XX, 614-622~(1988).
`
`‘
`
`3'. Fred D. Lasky, Donald M. Powers, David J. Hassemer, and Donald A.
`Wiebe: Quality of fluids used in external quality control programs affects
`the reliable assessment of accuracy of routine methods, as documented
`by cholesterol. in: Quality‘ Control in the Clinical Laboratory '91 Eds. T.
`Kawai, Y Ohba, et al. (Amsterdam: Excerpta Medica, 1992), pp 199-208.
`
`4. Donald'A. Wiebe: Lipids and lipoproteins beyond the year 2000.
`Presented at Frontiers in.Liplds‘ and Lipoproteins, Atlanta, GA Sept 93,
`in Atherosclerosis j_Q_8_ (suppl.) S181~S189_ (1994).,
`
`,
`
`~
`.
`,
`1
`Chapters in books:
`_
`'
`- 1. Donald J. Burton and Donald ‘A: Wiebe: Preparation of 2—
`Trifluoromethyl—333,Trifluoropropanoal. In Efficient Preparation of Fluorine
`Compounds. Ed H.W. Roesky, Wiley and ‘Sons; 2012, pp 250-1.
`
`«
`
`.1 2. Donald A. Wiebeand G. Russell Warnick: Measurement. othigh density '
`lipoprotein cholesterol concentration. in Methods for Clinical Laboratory
`-Measurement of Lipid and Lipoprotein Risk. Factors.'Eds. N. Rifai and
`G_.R. Warrlick, AACC Press, Washington DC, 1991, pp 61-74.
`~
`3. Donald A. Wiebe and Thomas Bpillman: Lipids and Lipoiproteins. in.‘
`- Clinical Chemistgg. Listen, Look and Learn Series from Health and
`Education Resources, Bethesda, 1991, pp 77-84.
`’
`4.. Donald A. Wiebe:‘ Lipids. in Clinical Laboratory Medicine. Eds. RC," 7
`- Tilton, A. Balows, D.C. Hohnadel, and R.F. Reiss, Mosby Year Book, St.
`Louis,.1992, pp_.12-5~134.
`’
`‘
`
`lnfopia’ Ex. 1022 pg. 11
`
`.
`
`,
`l
`
`
`
`

`
`5. Donald A.’Wiebe and Joseph D.Artiss: Lipids, Lipoproteins, and Z
`‘ Apoproteins. In Clinical Laboratory Medicine. Ed. l(.D. McClatchey,
`Williams and Wilkins, Baltimore, 1994, pp. 287-302.
`
`_
`
`,
`
`L
`
`3
`
`_
`
`r
`’
`
`1
`
`g
`‘
`
`6. Donald A.,Wiebe and G. Russell Warnick: Measurement of high— .
`density lipoprotein cholesterol concentration. In Laboratory Measurement
`of Lipids, Lipoproteins and Apolipoproteins Risk Factors. Eds. Nader Rifai
`and G. Russell Warnick, AACC Press, Wash DC, 1994, pp 91-105.
`.
`
`1‘
`7. Donald~A. Wiebe and G. Russell Warnick: Measurement of high-
`. density lipoprotein cholesterol concentration. In Handbook of Lipoprotein
`Testing. Eds. Nader Rifai, G. Russell Warnick, and Marek H. Domlniczak,
`AACC Press, Wash DC, 1997, pp." 127-144.
`4
`
`1
`
`I
`
`t,
`
`8. Matthias A. .Nauck, Donald A. Wiebe and G. Russell Warnick:
`Measurement of high~density. lipoprotein cholesterol concentration. in
`Handbook of Lipoprotein Testing. Eds. Nader Rifai, G.» Russell Wamlck,
`and Marek H. Dominiczak,‘AACC‘Press, Wash DC, 2000 pp. 221-244.
`
`Contributed papers and/or abstracts:
`
`1. Donald ‘A. Wiebe and Donald J. Burton: The selective halogenation of
`'a—hydrofluori_nated aldehydes. American Chemical Society, Abstract of
`Papers jg}: FLUO 021 (1972).
`‘
`'
`
`, 2. D. Wiebe, R. D. Feld, and D. L. Witte: Lipoprotein associated
`alkaline phosphatase. _C_li_n. Chem. .25: 1155 (1979).
`~
`‘
`
`3. o. R. Flores, R. Ferd, D. Wiebe, and .1. Pfhold: Total and HDL
`cholesterol measurement by oxygen rate methodology ~— from the
`, research environment to the clinical laboratory. _C_li_n. Chem. ;5_:_ 1074
`(1979).
`'
`~
`
`.4. ‘CD. A. Wiebe, D. L. Witte, and R. D. Feld: Alkaline phosphatase and
`gamma glutamyl transferase associated with lipoproteins. Cm Chem.
`._2_€j:1027 (1980).
`’ "
`'«
`.
`'
`A ,
`,
`1’
`
`5. D. A. Wiebe, J. S. Hazlehurst, and G.~R. Cooper: E\ialuatlon‘of _
`interference from manganese chloride in enzymatic measurement of
`‘ high~denslty lipoprotein cholesterol (HDL-C) with phosphate~buffered
`reagents. %. Chem. 21: 1046 (1981).
`.
`“
`
`~
`
`,
`
`1 6. David D. kooh, Mary M. Cypert, and Donald A. Wiebe: Evaluation of
`the Ames Seralyzer solid phase reflectance, potassium method. §_li_n.
`()l1jem._§l_e966(1985). ,
`'
`V
`‘
`‘
`'
`‘
`A
`,7. D. A. Wiebe, D. D. Koch,’ B.- Fields, and H. Sollinger: Pancreas
`transplant; rejection ‘episodes monitored by urine amylase measurement;
`_3_2_: 1139 (198_6).'
`’
`»
`'
`‘
`
`‘
`
`.
`
`~’
`
`lnfopia Ex. 1022 pg. 1i2‘:"_‘_ ,
`
`

`
`l. Bruce Rosenzweig',‘Ernest C..Borden, Donald A. Wiebe, Barry .
`,8.
`Storer, and Earl S, Shrago: Dose-dependent hypocholesteroiemic
`response induced by INF Bserin man. Presented at the international
`’ Society for interferon Research, Finland. (1986).
`.
`’
`
`A
`
`r 9. Donald_A. Wiebe, l. Bruce Rosenzweig, Frank V. Ruzicka, Earl S.-
`_ Shrago, and Ernest C. Borden: Selective association of high density
`iipoprotein (HDL) with interferon bets serine. Presented at the
`international Society for Interferon Research, Finland (1986).
`
`S. Shrago, and E. C. Borden:
`l. B. Rosenzweig, D.‘A. Wiebe,
`10.
`Effect of interferon beta serine and plasma iipoproteins in renal cell
`carcinoma patients. FASEB 4_5: 844 (1987).
`'
`~
`
`11. Scott Reich, Donald Wiebe, and David Kochzrlnterference from)‘.
`immunoglobins in the Hitachi 737 endpoint urease method for blood
`urea nitrogen (BUN). Qljg. Chem._fi 1010 (1987).
`
`. 12. Dennis Dowd, David Koch, Donald Wiebe, and Donald Feldbrueggez
`Development of a rate BUN method for use on the Hiachi737. Q_li_n. Chem.
`’;3_§1010(1987)..'
`
`, 13. Gary Lensmeyer, Donald Wiebe, and ian Carlson: Temperature-
`dependent distribution of cyclosporine (CsA) metabolites amongst
`cells/plasma in whole blood. flu. Chem. Q 979 (1987).
`
`14._ Donald Wiebe, David Hassemer, and Tim Kramer: Wisconsin
`cholesterol survey: Presented at the NBS: Clinical Laboratory
`Measurements: Accuracy and Patient Needs meeting,’ Maryland, October,
`(1988).
`»
`
`1
`
`15. Michael J. Strassman, Mary Muckerheide, Karen Mugan, Gay
`McManamy, Rhee Kim, Barbara Darcey, Ian Carlson, and Dona'ld~A.
`Wiebe: Evaluation of the Abbott TDX whole blood cyclosporine assay.
`Qflg. Chem. E: 1289 (1988).
`’
`'
`‘
`
`18. Gary. Lensmeyer, Diane devos, Jane Horswill,*Deborah Rohde, Ian
`’ Carlson, and Donald Wiebe: Cross reactivity study of cyclosporine
`1 metabolites with three commercial whole blood immunoassays. Q_ii_n_.
`Chem. 35: 1269 (1988).
`.
`‘
`
`- 17. David J. Hassemer, David D. Koch, and Donald A. Wiebe: Four
`commercially -available cholesterol methodsmeet 199'2,,NCEP. guidelines.
`g_e_m_g:12s’1,(198a)..
`‘
`- M
`A 18. P. E. McBride, M.B. Plane, and D. Wiebe: Apolipoproteins A-l and B
`in young adults: Associations with CHD risk factors. Presented at the .
`' National Heart, Lung, and Blood institute's PCAA 10th Annual Meeting in
`‘Bethesda, Md, April (1989).
`~-
`V
`-
`
`lnfopia Ex. 1022 pg. 13
`
`'
`
`i
`
`s
`
`'
`
`

`
`~19. Dav,id,.J. Hassemer, Tim Kramer, and Donald Wiebe: The Wisconsin
`cholesterol study-an assessment of laboratory performance. Presented ‘
`.)at the National Cholesterol Conference, Washington, D.C., November
`(1989).
`‘
`1
`‘
`
`A
`
`‘
`
`, Koch:
`
`20.. Martina Tse, Donald Feldbruegge, Donald Wiebe, and David D.
`Accurate cholesterol results by modification. of Roche. enzymatic metho
`parameters.
`Chem. Q: 1068 (1989).
`'
`
`' 21. David J. Hassemer, Donald Wiebe, and Tim Kramer: The Wisconsin
`cholesterol stu;;ty—an assessment of laboratory performance. §flr_1. Chem.
`35: 1068 (1989).
`1
`‘
`
`22. ED Lasky, DM Powers, DJ Hassemer, and DA Wiebe: Cholesterol
`determination in proficiency testing fluids is inadequate to demonstrate
`accuracy in patient specimens. Presented at 8th European Congress of
`Clinical Chemistry (lF.C.C), Milan, Italy, June, 1989.
`
`23. RR Love, DA Wiebe, and DL DeMets: Effects of tamoxifen in
`postmenopausaiwomen after 12 months: results from a controlled trial.
`Presented at 15 international Cancer Congress, Hamburg, Germany,
`August 1990.
`‘
`'
`'
`'
`
`.24. we Miller, J Levine, M Santulli, KJ From, N Greenberg. A Kessner,'W
`, O‘Neal, and DA Wiebe: Effect of freezing on cholesterol in individual
`sera. gin. Chem. ffiz 965 (1990).
`'
`
`25. Gary L. Lensmeyer and Donald A. Wiebe: Application of the Empore _
`extraction disk to the analysis of amiodarone and its metabolite. gin.
`«Chem. E: 1048 (1990). .
`
`26. Michael A. Poquette and Donald A. Wiebe: Single screening
`lconfirmation urine drug analysis.
`Chem. Q3; 1026 (1990).
`_
`— 27. Gary L. Lensmeyer and Donald A. Wiebe: Application of the Empore
`solid—phasezextraction diskto‘ isolation of drugs from blood~:‘Presented at
`the Minnesota Chromatography Forum, St. Paul, MN, March 1990.
`
`Wiebe: Target
`28. F.D. Lasky; D.l\/l.,Powe,rs, D.J. Hassemer, and
`value‘assign‘m"ent in proficiency testing programs: is usingreference '
`methods a valid approach? C_li11_. Chem. 37: 957 (1991).
`"
`‘
`
`’
`
`4 29. Richard R. Love, Donald A.‘Wiebe, Jan M. Fryzi, Polly A. Newcomb,
`and David L. DeMets: Effects of tamoxifen on cardiovascular risk factors .
`in postmenopausal women ‘after 5 years. Presented at the‘1993 ASCO
`s
`_meeting in Orlando, FL.
`
`; 30. Kay ‘A. Ringelstetter, Donald H. Feldbruegge, JoAnn M. Golesh, and
`Donald" A. Wiebe: Evaluation of INCSTAR Lp(a) kit method on the Cobas '.
`FARA ll.
`Chem. 39: 1124 (1.993).'
`'
`»
`~
`I
`'
`
`lnfopia Ex. 1022 pg. 14
`
`
`
`

`
`'
`31. G..L. Lensmeyer,VD. A.‘Wiebe;. and D. A. Wells: Extraction. of
`amiodarone and desethylaminodarone from serum using paiticle—loaded
`'membranes:,method optimization and comparison to large particle SPE
`~ columns. Presented at the Pittsburgh Conference, Chicago, March 1994.
`
`,
`
`32. ' Gary L. Lensmeyer, lan H. Carlson, Donald A. Wiebe, and Carol
`Onsager: Use of particle—loaded membranes to extract serum steroids for
`HPLC analysis: improved analyte stability and detection. Presented at
`Liquid 'C‘h‘ro'matography,
`the 18th International Symposium on Column
`Minneapolis, MN, May 1994.
`.
`
`'
`
`,
`
`V
`
`33. Elin Olafsdottir, Donald A, Wiebe, and James O. Westgard:
`performancespecifications for triglycerides and HDL cholesterol
`Analytical
`' based
`on proficiency testing outcome criteria. Presented at CDC's
`Frontiers in Laboratory Practice Research, Atlanta, GA, October, 1995.’
`
`Medic
`
`P
`
`_
`34. Elin Olafsdottir, Donald A, Wiebe, and James O. V\'/estgard:
`ally
`relevant performance specifications for triglycerides and HDL
`, cholesterol based on clinical decision intervals. Presented at CDC‘s
`Frontiers inlaboratory Practice Research, Atlanta, GA, October, '1 9.95.
`
`35‘. JB Watson, JM Golesh, LM Sabatini, KV Voelkerding, and DA Wiebe:
`Optimization of a PCR—RFLP based apoliporotein E genotyping assay.
`Presented at the Association for Molecular Pathology meeting,
`Minneapolis, MN, November 1995.
`‘~
`
`'36. Gary Lensmeyer and Donald Wiebe: Lamotrigine and three other
`anticonvulsant drugs, measured concominantly in serum using disk
`extraction and HPLC. _C_l_ig. Chem’. Q: 8218 (1996).
`
`37. Patti Fallest~Strobl, Elin Olafsdottir,_Donald A, Wiebe, and. James O.
`Westgard:_ Comparison of NCEP performance specifications for‘ .
`'
`triglycerides, HDL, and LDL cholesterol with operating specifications .
`based on‘NCEP clinical and analytical goals.
`Chem.’ 4;: S272
`(1996).
`'
`‘
`'
`.
`
`~
`
`38. Barbara M. Hill, David J. Hassemer, and Donald A. Wiebe. Long-
`term stability of human based serum cholesterol pools prepared by,
`‘ standard addition. Presentation at the Frontiers in Lipid and Lipoprotein
`» -Research Meeting, Dallas, TX,'October,,19,9_6.
`
`39. Nader Rifai, Elizabeth lannotti, 'l'erence Law, Thomas G. Cole,'Anne
`Schmitt, Michael Macke, Donald A. Wiebe, Dennis E. Dowd, Richard C.
`r Miller. Multicenter evaluation of.Boeh‘ringer Mannheim Corporation’s
`automated direct HDL-cholesterol assay using Hitachi analyzers.
`.
`--
`Accepted for presentation at the National AACC meeting, Atlanta, GA;
`July, 1997
`’
`»
`l
`.
`
`‘
`
`’
`
`.
`
`|nfopia‘Ex. 1022 pg. 151‘
`
`

`
`40.‘Todd M Allen, John Sidney, Marie—France del_Guerico, Rhonda L
`Glickman, Gary L Lensmeyer, Donald A Wiebe, C David Pauza, R Paul
`Johnson, Alessandro.Sette, David I Watkins. ‘Characterization